Related by context. All words. (Click for frequent words.) 76 metastatic colorectal cancer 76 HRPC 73 castration resistant prostate cancer 72 HER2 positive metastatic breast 71 advanced NSCLC 71 metastatic hormone refractory 71 B CLL 71 NSCLC 70 metastatic renal cell carcinoma 70 metastatic breast cancer 70 mRCC 69 lymphoma CTCL 69 castrate resistant prostate cancer 68 mCRC 68 phase IIb clinical 68 cutaneous T cell 67 docetaxel 67 HER2 positive breast cancer 67 metastatic castration resistant 67 recurrent NSCLC 67 metastatic CRPC 66 glufosfamide 66 chronic lymphocytic leukemia CLL 66 cell lymphoma CTCL 66 prostate cancer CRPC 66 metastatic renal cell 66 resistant ovarian cancer 66 Amrubicin 66 metastatic castrate resistant 66 metastatic HRPC 65 refractory multiple myeloma 65 platinum refractory 65 prostate cancer HRPC 65 temsirolimus 65 androgen independent 65 docetaxel chemotherapy 65 unresectable 65 leukemia AML 65 Vectibix 65 registrational trial 65 HER2 positive 65 axitinib 64 luteinizing hormone releasing 64 metastatic melanoma 64 metastatic CRC 64 acute myelogenous leukemia AML 64 tesetaxel 64 relapsed refractory multiple myeloma 64 gastrointestinal stromal tumor GIST 64 adecatumumab 64 stage IIIB 64 renal cell carcinoma 64 gemcitabine 64 Proxinium TM 64 metastatic prostate cancer 64 bone metastases 63 unresectable locally advanced 63 dirucotide 63 ELACYT 63 mTOR inhibitor 63 mCRC patients 63 recurrent ovarian cancer 63 gastrointestinal stromal tumors 63 SCCHN 63 superficial bladder cancer 63 cell lung cancer 63 non squamous NSCLC 63 alvespimycin 63 oral ridaforolimus 63 leukemia CLL 63 monotherapy 63 advanced unresectable 63 Phase 2a trial 62 remission induction 62 indolent NHL 62 metastatic NSCLC 62 vinorelbine 62 multiple myeloma MM 62 OncoVEX GM CSF 62 plus prednisone 62 hepatocellular cancer 62 vandetanib 62 relapsed multiple myeloma 62 gemcitabine chemotherapy 62 advanced metastatic prostate 62 metastatic RCC 62 Phase IIb clinical 62 cetuximab Erbitux ® 62 multiple myeloma 62 fallopian tube carcinoma 62 lupus nephritis 62 prostate cancer AIPC 62 randomized Phase 62 relapsed ovarian cancer 62 erlotinib 62 Phase 2b clinical 62 FOLOTYN 62 refractory cutaneous T 62 BAY #-# 62 goserelin 62 metastatic gastric 62 Phase 2b study 62 metastatic colorectal 62 KRAS wild 61 HGS ETR1 61 forodesine 61 heavily pretreated 61 acute myeloid leukemia AML 61 carboplatin paclitaxel 61 paclitaxel carboplatin 61 trastuzumab 61 relapsing remitting multiple sclerosis 61 chronic myeloid leukemia CML 61 nilotinib 61 Acute Myeloid Leukemia AML 61 Genasense ® 61 Ceflatonin 61 Targretin 61 assessing T DM1 61 imatinib resistant 61 imatinib therapy 61 IV metastatic melanoma 61 temozolomide 61 sapacitabine 61 IV NSCLC 61 gefitinib 61 hematological cancers 61 dasatinib 61 lintuzumab SGN 61 YONDELIS 61 docetaxel Taxotere R 61 registrational 61 AA amyloidosis 61 Phase 2b trial 61 metastatic GIST 61 dasatinib Sprycel ® 61 metastatic carcinoma 61 docetaxel Taxotere ® 61 MDV# 61 EFAPROXYN 61 T#I mutation 61 sunitinib 60 Troxatyl 60 taxane 60 INCB# [001] 60 Tarceva erlotinib 60 refractory metastatic colorectal cancer 60 evaluating picoplatin 60 EGFR expressing 60 picoplatin 60 tumors GIST 60 pralatrexate 60 pomalidomide 60 myelodysplastic syndromes MDS 60 T DM1 60 myelodysplastic syndrome MDS 60 Cloretazine ® 60 cutaneous T 60 non metastatic osteosarcoma 60 symptomatic BPH 60 pancreatic NET 60 metaglidasen 60 malignant pleural mesothelioma 60 taxane chemotherapy 60 pivotal Phase 60 refractory AML 60 Vicinium TM 60 Fludara ® 60 aflibercept 60 cabazitaxel 60 nonsmall cell lung cancer 60 refractory NSCLC 60 Taxotere ® 60 investigational compound 60 HER2 negative 60 IV melanoma 60 RG# [001] 60 cytotoxic therapy 60 recurrent glioblastoma multiforme 60 oxaliplatin 60 Cloretazine R VNP#M 60 gefitinib Iressa 60 phase IIa clinical 60 Ozarelix 60 recurrent prostate cancer 60 elacytarabine 60 pivotal Phase III 60 hematological malignancies 60 follicular NHL 60 brain metastases 60 ixabepilone 60 erlotinib Tarceva ® 60 custirsen 60 Cloretazine 60 nab paclitaxel 60 Clolar ® 60 systemic ALCL 60 chemoradiotherapy 60 metastatic colorectal carcinoma 60 Nexavar sorafenib 60 perifosine 60 HER2 + 60 prostate cancer mCRPC 60 soft tissue sarcoma 60 evaluating T DM1 60 chemotherapy regimens 60 low dose cytarabine 60 dacarbazine 60 abiraterone acetate 60 carboplatin 60 Nexavar ® 60 idiopathic pulmonary fibrosis IPF 60 sorafenib 59 Metastatic Colorectal Cancer 59 chlorambucil 59 hematologic malignancies 59 Bezielle 59 IRESSA 59 myelofibrosis 59 pancreatic adenocarcinoma 59 PNP inhibitor 59 estramustine 59 cetuximab Erbitux R 59 refractory chronic lymphocytic 59 follicular non 59 PSMA ADC 59 stage IIIb IV 59 AVASTIN 59 Onalta ™ 59 mapatumumab 59 voreloxin 59 sorafenib Nexavar 59 IRX 2 59 metastatic disease 59 relapsed refractory 59 Amigal 59 pancreatic carcinoma 59 sorafenib tablets 59 zalutumumab 59 Hepatocellular Carcinoma HCC 59 depsipeptide 59 bevacizumab Avastin 59 solid tumors 59 obatoclax 59 Phase #/#a trial 59 Pirfenidone 59 CRPC 59 metastatic androgen independent 59 panitumumab 59 Fludara 59 bevacizumab Avastin ® 59 AEG# 59 recurrent glioblastoma 59 OPAXIO 59 unresectable stage 59 tamibarotene 59 afatinib 59 irinotecan 59 trastuzumab Herceptin ® 59 tyrosine kinase inhibitors 59 TBC# 59 Torisel 59 medullary thyroid cancer 59 cell chronic lymphocytic 59 FOLFIRI 59 hormone refractory 59 non alcoholic steatohepatitis 59 pegylated liposomal doxorubicin 59 nucleoside analogue 59 Folotyn 59 enzastaurin 59 novel histone deacetylase 59 refractory gout 59 EGFR expressing mCRC 59 metastatic malignant melanoma 59 MYDICAR ® 59 belinostat 59 gastrointestinal stromal tumors GIST 59 relapsing remitting MS RRMS 59 AP# [003] 59 non squamous 59 MAGE A3 ASCI 59 immunotherapeutic agent 59 imatinib Gleevec 59 lumiliximab 59 castration resistant 59 TTF Therapy 59 lapatinib 59 Phase 2a clinical 59 Ophena TM 59 metastatic pancreatic cancer 59 metastatic 59 LHRH receptor positive 58 Herceptin trastuzumab 58 cediranib 58 diagnosed multiple myeloma 58 Rituxan rituximab 58 opioid induced constipation OIC 58 Glufosfamide 58 radiation sensitizer 58 soft tissue sarcomas 58 alkylating agents 58 interferon gamma 1b 58 Phase IIb trial 58 proteasome inhibitor 58 oral deforolimus 58 talactoferrin 58 sorafenib Nexavar ® 58 hepatocellular carcinoma HCC 58 cetuximab Erbitux 58 EOquin 58 Insegia 58 trastuzumab Herceptin R 58 IMC A# 58 Gleevec imatinib 58 Xcytrin 58 relapsed MM 58 RDEA# 58 PD LID 58 VIDAZA 58 HuMax CD4 58 myelodysplastic syndromes 58 neoplasia 58 metastatic colon cancer 58 liver metastases 58 refractory CTCL 58 alkylating agent 58 MGCD# [001] 58 antitumor activity 58 Aflibercept 58 decitabine 58 TREANDA 58 Asentar 58 Phase Ib 58 PROVENGE sipuleucel T 58 heavily pretreated patients 58 HGS ETR2 58 TELINTRA 58 PANVAC VF 58 tafamidis 58 PDX pralatrexate 58 Pemetrexed 58 multi kinase inhibitor 58 ADVEXIN 58 Phase IIa trial 58 gemcitabine carboplatin 58 INCB# [002] 58 Perifosine 58 lintuzumab 58 SCH # 58 TACI Ig 58 Zolinza 58 Xanafide 58 hypoparathyroidism 58 SPRYCEL ® 58 pertuzumab 58 AGILECT R 58 pancreatic neuroendocrine tumors 58 pegylated interferon alpha 58 Phase Ib study 58 Platinol 58 Phase Ib II 58 eosinophilic asthma 58 Phase III clinical 58 recurrent malignant glioma 58 ozarelix 58 recurrent metastatic 58 Taxotere R 58 generation purine nucleoside 58 Voreloxin 58 Azixa 58 standard chemotherapy regimen 58 histone deacetylase HDAC inhibitor 58 Motesanib 58 Ixempra 58 cetuximab 58 imatinib Gleevec ® 58 CYT# potent vascular disrupting 58 rNAPc2 58 BRAF mutation 58 Gemzar ® 58 idarubicin 58 Phenoptin 58 trabectedin 58 figitumumab 58 abiraterone 58 Ceflatonin R 58 Tarceva TM 58 aflibercept VEGF Trap 58 Aplidin 58 CA4P 58 amrubicin 58 metastatic bladder 58 FOLFOX regimen 58 stage IIIB IV 58 Gleevec resistant 58 Dapagliflozin 58 refractory PTCL 58 EGFR expressing metastatic colorectal 58 Irinotecan 58 paclitaxel poliglumex 58 Avastin bevacizumab 58 pan HDAC inhibitor 58 Advanced Renal Cell 58 OvaRex ® MAb 58 Marqibo 58 BRIM3 58 L MTP PE 58 infusional 5-FU/LV 58 Alpharadin 58 differentiated thyroid 58 Phase 1b clinical 58 BRIM2 58 capecitabine 58 Tavocept 58 gemcitabine Gemzar 58 Azedra 58 chronic HCV 57 familial amyloidotic polyneuropathy FAP 57 CHOP chemotherapy 57 TELCYTA 57 Aurexis 57 stage IIIb 57 trastuzumab DM1 T DM1 57 hormone LHRH antagonist 57 Traficet EN 57 Hodgkin lymphoma NHL 57 randomized Phase III 57 SUCCEED trial 57 cancer mCRC 57 TORISEL 57 Telintra 57 epithelial tumors 57 irinotecan containing 57 Sutent sunitinib 57 vemurafenib 57 ganetespib 57 Acute Myelogenous Leukemia AML 57 lenalidomide Revlimid R 57 lesinurad 57 adjuvant radiation 57 refractory prostate cancer 57 refractory ovarian cancer 57 refractory acute myeloid 57 IMA# 57 PRTX 57 Omacetaxine 57 HNSCC 57 hepatocellular carcinoma 57 octreotide implant 57 EGFR TKI 57 visilizumab 57 chronic angina 57 Erlotinib 57 entinostat 57 HCV protease inhibitor 57 MEK inhibitor 57 relapsed SCLC 57 investigational drug 57 sodium glucose cotransporter 57 ZYBRESTAT 57 fluoropyrimidine 57 Annamycin 57 aHUS 57 virus HCV protease inhibitor 57 Tyrima 57 sunitinib malate 57 Clevudine 57 baminercept 57 leading oral taxane 57 taxane refractory 57 iniparib 57 orally administered inhibitor 57 advanced metastatic renal 57 vascular disrupting agent 57 bone metastasis 57 carfilzomib 57 biliary tract cancer 57 Doxil ® 57 Phase 2b 57 taxane therapy 57 IMPACT IMmunotherapy 57 CD# antibody [001] 57 irinotecan doxorubicin oxaliplatin paclitaxel 57 Uricase PEG 57 leukemia ALL 57 imetelstat 57 secondary hyperparathyroidism 57 anthracyclines 57 Jevtana 57 relapsed leukemia 57 antibody MAb 57 PRT# 57 Mipomersen 57 grade cervical intraepithelial 57 Cloretazine R 57 Clofarabine 57 Virulizin ® 57 Abiraterone acetate 57 minimally symptomatic 57 octreotide 57 Apoptone 57 Dasatinib 57 HGS# 57 placebo controlled Phase 57 IgG1 monoclonal antibody 57 dacetuzumab 57 imatinib mesylate 57 MPS IVA 57 DMARD 57 CR# vcMMAE 57 bendamustine 57 pemetrexed 57 Phase Ib clinical trials 57 PI3K/Akt pathway inhibitor 57 trastuzumab emtansine T DM1 57 dimebon 57 interferon alfa 2b 57 pseudobulbar affect PBA 57 refractory metastatic 57 vinca alkaloid 57 imatinib mesylate Gleevec 57 phenoxodiol 57 Zytiga 57 carcinoma HCC 57 receptor tyrosine kinase inhibitor 57 3 registrational trial 57 hormone LHRH agonist 57 anti leukemic 57 metastatic kidney 57 T#I [002] 57 basal cell carcinoma BCC 57 plus dexamethasone 57 untreated multiple myeloma 57 thymalfasin 57 Alzhemed TM 57 Pegasys ® 57 chemotherapy cisplatin 57 ponatinib 57 BENLYSTA TM 57 5 fluorouracil 57 EGFR mutation 57 PROVENGE 57 tesmilifene 57 Dacogen injection 57 PLX# 57 evaluating ispinesib 57 romiplostim 57 CEQ# 57 zanolimumab 57 docetaxel Taxotere 57 INCB# [003] 57 milatuzumab 57 Faslodex 57 investigational immunotherapy 57 Fibrillex TM 57 Satraplatin 57 FOLFOX6 57 Genasense 57 daunorubicin 57 PXD# 57 plus gemcitabine 57 Gefitinib 57 CALGB # [001] 57 humanized anti 57 tyrosine kinase inhibitor 57 palifosfamide 57 biologic therapy 57 modified glutathione analog 57 clinically localized prostate 57 metastatic pancreatic 57 Luteinizing Hormone Releasing Hormone 57 purpura ITP 57 clofarabine 57 5-FU/LV 57 ONCONASE 56 cytarabine 56 IMGN# 56 gemcitabine Gemzar ® 56 fludarabine 56 refractory Hodgkin lymphoma 56 satraplatin 56 paclitaxel Taxol ® 56 rheumatoid arthritis psoriatic arthritis 56 systemic lupus erythematosus SLE 56 mixed dyslipidemia 56 nucleoside analog 56 LEUKINE 56 huC# DM4 56 atypical Hemolytic Uremic Syndrome 56 relapsed AML 56 hormone receptor positive 56 previously untreated follicular 56 PEGylated interferon beta 1a 56 evaluating tivozanib 56 eculizumab 56 angiogenesis inhibitor 56 pediatric malignancies 56 cangrelor 56 EGFR inhibitors 56 tocilizumab 56 dose cohorts 56 Sudhir Agrawal D.Phil 56 Junovan 56 systemic anaplastic large 56 metastatic SCCHN 56 FOLFOX chemotherapy 56 HCV RESPOND 2 56 Phase III randomized controlled 56 AEGR 56 TEMODAL 56 adjuvant therapy 56 MOZOBIL 56 anthracycline taxane 56 LHRH analogues 56 regorafenib 56 diabetic neuropathic pain 56 CLL 56 doxorubicin HCl liposome injection 56 lorvotuzumab mertansine 56 hormone deprivation 56 Curaxin CBLC# 56 metastatic sarcomas 56 CIMZIA ™ 56 GRN#L 56 paclitaxel Taxol 56 recurrent GBM 56 CoFactor 56 Miraxion 56 imatinib 56 Clolar 56 Alocrest 56 BRAF V# mutation 56 tanespimycin 56 ONTAK 56 AQ4N 56 ribavirin RBV 56 relapsed CLL 56 ToGA 56 localized prostate cancer 56 MyVax R 56 REVLIMID ® 56 pain palliation 56 chronic ITP patients 56 free survival PFS 56 Treanda 56 CTAP# Capsules 56 hereditary deficiency 56 Kit CD# positive 56 phase IIb trial 56 dasatinib Sprycel 56 LUX Lung 56 Phase IIIb clinical 56 PKC# 56 Campath ® 56 ocular formulation 56 JAK inhibitor 56 ongoing Phase 1b 56 FOLFOX4 56 Brentuximab Vedotin SGN 56 Azilect ® 56 valopicitabine 56 phase IIb study 56 alvimopan 56 MabCampath 56 glioblastoma multiforme GBM 56 paclitaxel Taxol R 56 liposomal formulation 56 follicular lymphoma FL 56 sipuleucel T 56 dexamethasone Decadron 56 Phase 1b 56 colorectal cancer liver metastases 56 Phase III clinical trials 56 Navelbine ® 56 autologous cellular immunotherapy 56 advanced hepatocellular carcinoma 56 Myocet 56 cisplatin gemcitabine 56 PEGINTRON TM 56 CBLC# 56 N acetylgalactosamine 6 56 immunomodulatory therapy 56 XELOX 56 GVAX 56 follicular lymphoma 56 cisplatin chemotherapy 56 ZOLINZA 56 pegylated interferon alfa 2a 56 IMiD 56 Ophena 56 interferon alfa 56 chronic plaque psoriasis 56 Ocrelizumab 56 huN# DM1 56 androgen deprivation 56 HspE7 56 Phase #b/#a clinical 56 trastuzumab DM1 56 Phase 2a 56 ACTEMRA TM 56 relapsing MS 56 acute GvHD 56 castrate resistant 56 chemotherapeutic agent 56 trabedersen 56 Taxotere chemotherapy 56 PEG SN# 56 VELCADE melphalan 56 PAOD 56 systemic lupus erythematosus 56 elagolix 56 Plicera 56 Prostate AdenoCarcinoma Treatment 56 Trastuzumab 56 RoACTEMRA 56 ASA# 56 overactive bladder OAB 56 TRISENOX 56 IL# PE#QQR 56 refractory chronic myeloid 56 ADXS# 56 ELND# 56 dirucotide MBP# 56 epothilone 56 PEG INTRON 56 Golimumab 56 ospemifene 56 topotecan 56 Viramidine 56 hypercalcemia 56 neuroendocrine tumors 56 resectable 56 dose cohort 56 relapsing multiple sclerosis 56 hormone LHRH 56 Ceflatonin ® 56 Degarelix 56 Bevacizumab 56 PROSTVAC TM 56 anthracyclines taxanes 56 investigational humanized monoclonal antibody 56 chemotherapy regimen 56 ataluren 56 anti TNF alpha 56 PRX # 56 elotuzumab 56 VEGF receptor inhibitor 56 romidepsin 56 atrial fibrillation budiodarone ATI 56 Lenocta 56 trastuzumab Herceptin 56 indolent follicular non 56 Fludarabine 56 SNT MC# 56 nilotinib Tasigna ® 56 AVOREN 56 Hodgkin lymphoma HL 56 Phase Ib clinical 56 gastric cancer 56 cilengitide 56 KRAS mutations occur 56 Androxal TM 56 ovarian lung 56 anti EGFR antibody 56 R sorafenib tablets 56 acute leukemias 56 ON #.Na 56 hepatitis C HCV 56 epithelial ovarian 56 SHPT 56 Doxil 56 posaconazole 56 FOLOTYN ® 56 CANCIDAS 56 Gleevec imatinib mesylate 56 Ambrisentan 56 ofatumumab 56 Aurora kinase 56 Xeloda capecitabine 56 chronic myelogenous leukemia CML 56 PegIntron 56 achieve sustained virologic 56 vismodegib 56 refractory colorectal cancer 56 Metastatic breast cancer 56 Ph + ALL 56 carcinoid syndrome 56 metastatic malignant 56 anticancer compound 56 essential thrombocythemia 56 Androxal 55 taxane resistant 55 ambrisentan 55 hypercholesterolemic patients 55 CTA# Injection 55 Cytoxan 55 Riquent 55 untreated metastatic melanoma 55 recurrent colorectal cancer 55 HCV infected 55 calcineurin inhibitor 55 panitumumab Vectibix 55 neoadjuvant chemotherapy 55 5 fluorouracil leucovorin 55 resistant hormone refractory 55 Bortezomib 55 invasive bladder 55 irinotecan chemotherapy 55 HGS ETR1 mapatumumab 55 bortezomib 55 Hsp# inhibitor 55 rituximab 55 ALN TTR# 55 mertansine 55 pulmonary arterial hypertension PAH 55 olaparib 55 Cabazitaxel 55 Chronic Idiopathic Constipation 55 operable breast cancer 55 azacitidine 55 neoadjuvant 55 melphalan prednisone 55 virus HCV infection 55 R lenalidomide 55 PROVENGE ® 55 Pralatrexate 55 metastatic breast 55 unresectable liver cancer 55 disease modifying antirheumatic 55 investigational monoclonal antibody 55 Dupuytren Disease 55 Taxotere docetaxel 55 advanced carcinoid 55 breast carcinoma 55 KRAS status 55 phase III ACCLAIM 55 chronic HCV infection 55 primary hypercholesterolemia 55 methylnaltrexone 55 Cutaneous T 55 nonmetastatic 55 Tamibarotene 55 refractory indolent non 55 recurrent squamous cell carcinoma 55 FOLFOX6 chemotherapy regimen 55 LHRH agonists 55 FavId 55 mycophenolate mofetil 55 Renal Cell Carcinoma RCC 55 Panzem R 55 XGEVA 55 neoadjuvant therapy 55 generation Hsp# inhibitor 55 CIMZIA TM 55 antithrombotic 55 Telcyta 55 Cannabinor 55 EndoTAGTM 1 55 daclizumab 55 sodium thiosulfate STS 55 TNF antagonist 55 neurogenic orthostatic hypotension 55 ofatumumab HuMax CD# 55 pazopanib 55 Tocosol Paclitaxel 55 Tykerb 55 Folfox 55 CCX# 55 LymphoStat B 55 severe hypercholesterolemia 55 Phase IIa clinical 55 chemotherapeutic regimen 55 liposomal doxorubicin 55 EndoTAG TM -1 55 Panzem R NCD 55 Gabapentin GR 55 gastrointestinal stromal tumor 55 CYC# 55 EGFR mutations 55 Diabetic Macular Edema 55 Zerenex 55 placebo controlled clinical 55 Erbitux cetuximab 55 LHRH antagonist 55 Genz # 55 OHR/AVR# 55 urothelial bladder cancer 55 budesonide foam 55 Hsp# Inhibitor 55 unresectable Stage III 55 randomized Phase IIb 55 RCW Breast Cancer 55 oral chemotherapeutic agent 55 telaprevir dosed 55 leukemia CML 55 ularitide 55 Raptiva R 55 Acute Myeloid Leukemia 55 biochemical recurrence 55 epratuzumab 55 HCV SPRINT 55 farletuzumab 55 bevacizumab 55 COU AA 55 relapsing remitting MS 55 Gemcitabine 55 Hedgehog Pathway Inhibitor 55 interferon alfa 2a 55 Androxal ® 55 Xeloda ® 55 EDEMA4 55 Phase 1b trial 55 tyrosine kinase inhibitor TKI 55 ANCHOR trial 55 nonmetastatic prostate cancer 55 VNP#M 55 Stedivaze 55 Hormone Refractory Prostate Cancer 55 Solazed TM 55 Onrigin 55 dose cytarabine 55 Atiprimod 55 VEGFR2 inhibitor 55 cell malignancies 55 xenograft models 55 non resectable 55 Rituximab 55 oral prodrug 55 chemoradiation 55 papillary renal cell carcinoma 55 KRAS mutant tumors 55 Allovectin 7 R 55 benign prostatic hyperplasia 55 tivozanib 55 Vectibix panitumumab 55 CML CP 55 anti TNF 55 Imprime PGG 55 metastatic squamous cell carcinoma 55 BRAF inhibitor 55 pegylated interferon 55 epithelial ovarian cancer 55 protease inhibitor PI 55 Fx #A 55 phase Ib 55 Omnitarg 55 alpha folate receptor 55 advanced epithelial ovarian 55 refractory APL 55 Urocidin 55 BCG refractory carcinoma 55 zoledronic acid 55 FTY# 55 investigational compounds 55 IMiDs 55 Raptiva ® 55 situ CIS 55 XL# SAR# 55 Velcade bortezomib 55 Vandetanib 55 dose escalation trial 55 post herpetic neuralgia 55 leukemia APL 55 capecitabine Xeloda R 55 TYKERB 55 PEGINTRON 55 TNFerade 55 acute ischemic stroke 55 diarrhea predominant irritable 55 Phase IIb clinical trials 55 ibandronate 55 5-fluorouracil/leucovorin 55 Diamyd ® 55 Advexin 55 paclitaxel 55 glioblastoma 55 interferon beta 1a 55 bosutinib 55 neratinib 55 Tarceva 55 Evoltra TM 55 autoantibody positive 55 ENMD 55 Personalized Immunotherapy 55 lapatinib Tykerb 55 5 FU leucovorin 55 small lymphocytic lymphoma 55 bicalutamide 55 delivers fluocinolone acetonide FA 55 Debio 55 albinterferon alfa 2b 55 GPNMB 55 Intravenous CP 55 secondary hypogonadism 55 ThermoDox R 55 oral mucositis 55 pulmonary arterial hypertension 55 DAVANAT R